Study of Extracellular Vesicles (EV) in Patients Undergoing CAR-T Cell Therapies

Launched by IRCCS AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA · Aug 12, 2024

Keywords

ClinConnect Summary

This clinical trial is studying the role of tiny particles called extracellular vesicles (EVs) in patients who are receiving CAR-T cell therapy for blood cancers like lymphoma and leukemia. Researchers believe that these EVs may help predict how well patients respond to the treatment and if they experience any side effects, particularly neurological issues. The goal is to identify specific types of EVs that could serve as markers for these outcomes.

To participate in this study, individuals must be at least 18 years old and have certain types of blood cancers that are either not responding to treatment or have returned after treatment. Participants will need to give their written consent to join the trial. The study is currently recruiting, so eligible patients can expect to contribute to important research that may improve future CAR-T cell therapies. There are no specific exclusions, meaning if you meet the inclusion criteria, you could potentially take part in this impactful study.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • patients affeccted by any hematological malignancies (r/r B cell lymphoma, B cell acute leukemia and multiple myeloma) undergoing (or whit indication to) CAR-T cell infusion with a CAR-T cell product;
• • age: 18 years or greater;
• • obtained written consent to the study participation.
• Exclusion Criteria:
• • none